OS Therapies names Kerry Clem chief commercial officer
OSTX•OS Therapies named Kerry Clem chief commercial officer to lead U.S., U.K. and Europe launch planning for Herlystic. The company also appointed Frank Knuettel II chief financial officer as it prepares to transition toward commercialization.
1. Leadership appointments
Clem previously served as CEO of Solaxa and chief commercial officer at Acorda Therapeutics, and held commercial leadership roles at Allos Therapeutics. Knuettel most recently served as CFO of Pelthos Therapeutics and previously was CEO of Channel Therapeutics; he led more than 15 M&A deals.
